Novavax COVID-19 Vaccine shows 89.3% efficacy and more than 15 thousand people aged 18 to 84 took part in the clinical trials, including 27% over 65
According to the results of the third phase of clinical trials, the effectiveness of the vaccine of the American biotechnological company Novavax was 89.3%. This was announced on Thursday, January 28, by the press release.
“The vaccine against COVID-19, according to the results of the third phase of clinical trials conducted in the UK, showed an effectiveness of 89.3%,” the manufacturer said in a statement.
- Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
- New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
- Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
- New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
- Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean
It is specified that more than 15 thousand people aged 18 to 84 took part in the tests, 27% of them were over 65 years old.
Last July, Novavax announced that the US administration had allocated $ 1.6 billion to develop a vaccine against the coronavirus. The first phase of human clinical trials of this vaccine began in May in Melbourne, Australia.
In November, Bloomberg presented a ranking of the demand for vaccines against coronavirus.
Novavax was second place in the number of pre-orders (1.4 billion doses, of which 160 million – the USA, 100 million – Europe), the third – Johnson & Johnson (1.3 billion doses, of which 430 million – the United States, 300 million – European countries).
Most of the purchases in the world are for the vaccine of the British company AstraZeneca.